Milen Todorov

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann et al. · Journal of Medicinal Chemistry · 2020 · 106 citations · Full text

Reversible-covalent Inhibitor, Molecular Pharmacology, Signaling Pathway +19

Identification of the Structural Requirements for Mutagencitiy, by Incorporating Molecular Flexibility and Metabolic Activation of Chemicals. II. General Ames Mutagenicity Model

R. Serafimova, Milen Todorov, T. Pavlov et al. · Chemical Research in Toxicology · 2007 · 85 citations

Metabolic Simulator, Engineering, Metabolic Activation +25

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS^G12C for the Treatment of Solid Tumors

Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer et al. · Journal of Medicinal Chemistry · 2022 · 84 citations · Full text

Simulation of chemical metabolism for fate and hazard assessment. V. Mammalian hazard assessment

Ovanes Mekenyan, S. Dimitrov, T. Pavlov et al. · SAR and QSAR in environmental research · 2012 · 45 citations

Engineering, Model Refinement, Metabolic Model +24

Identifying the Structural Requirements for Chromosomal Aberration by Incorporating Molecular Flexibility and Metabolic Activation of Chemicals

Ovanes Mekenyan, Milen Todorov, R. Serafimova et al. · Chemical Research in Toxicology · 2007 · 35 citations